ClinicalTrials.gg
CompletedNCT03808688Updated Sep 29, 2020Results posted

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

A Phase 4 interventional study of Netarsudil Ophthalmic Solution 0.02% in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Aerie Pharmaceuticals. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-29.

Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
261
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.

Enrollment
5th of 17
261 · median 85
Started
2018
the only one that year
Phase 4
5 of 17
3 open now
Registered
9th of 17
by date
Lead sponsor
11 of 17
Aerie Pharmaceuticals

Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 5th largest by enrollment, is the only one that started in 2018, is one of 5 in phase 4, and was the 9th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About netarsudil

netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing netarsudil in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

To evaluate the IOP lowering efficacy of netarsudil ophthalmic solution 0.02% when used as monotherapy or when used concomitantly with other IOP-lowering agents in subjects with elevated IOP due to open angle glaucoma or ocular hypertension in a real-world clinical setting. The study is an open-label design. The patients will receive treatment for 12 weeks.

03

Conditions studied

  • Glaucoma, Open-Angle
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female subjects (aged 18 or older)
  2. Subjects diagnosed with open-angle glaucoma or ocular hypertension, and determined by the treating physician to require additional intraocular pressure (IOP)-lowering treatment with netarsudil 0.02%.
  3. Willingness to follow protocol requirements, including signed , routine follow-up schedule, completing questionnaires and completing laboratory tests

Key Exclusion Criteria:

  1. Have any active ocular disease other than glaucoma or ocular hypertension that would interfere with study interpretation
  2. Women of who are pregnant, nursing, or planning a pregnancy and not using a medically acceptable form of . Male subjects with a female partner of childbearing potential must have had a prior vasectomy or agree to use an effective method of birth control during the treatment period and for 3 months after the subject has completed the study.
  3. Known sensitivity or allergy to the study medication or components
  4. Any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results
  5. Concurrent participation or prior participation in any drug or device study within the last 30 days prior to the Baseline Visit
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
261 participants (actual)

Study arms

  • Other
    Netarsudil Ophthalmic Solution 0.02%

    Drug: Netarsudil Ophthalmic Solution 0.02%

Interventions

06

What researchers measure

Primary outcomes

  1. Intraocular Pressure (IOP)

    Percent Change from Baseline IOP at Week 12, as measured by Goldmann applanation tonometry. Prostaglandin analog (PGA). Fixed dose combination (FDC).

    Time frame: 12 weeks

07

Results

Posted Sep 29, 2020

Participant flow

A total of 261 subjects were enrolled across 22 investigational sites and 260 treated.

Participant flow — Overall Study
MilestoneNetarsudil Ophthalmic Solution 0.02% MonotherapyNetarsudil Ophthalmic Solution 0.02% Concomitant Therapy
Started99161
Completed81138
Not completed1823
Withdrew: Adverse event1317
Withdrew: Lack of efficacy20
Withdrew: Lost to follow-up02
Withdrew: Withdrawal by subject10
Withdrew: Intolerance to conjunctival hyperemia10
Withdrew: Iop too high11
Withdrew: Iop too high, nerve/visual field changes01
Withdrew: Visit out of window01
Withdrew: Medication non-compliance01

Outcome measures

PrimaryIntraocular Pressure (IOP)

Percent Change from Baseline IOP at Week 12, as measured by Goldmann applanation tonometry. Prostaglandin analog (PGA). Fixed dose combination (FDC).

Time frame:
12 weeks
Reported as:
Mean · percent change
Intraocular Pressure (IOP)
percent changeNetarsudil Ophth Sol 0.02% Monotherapy - Tx Naïve At BaselineNetarsudil Ophth Sol 0.02% Monotherapy - Replaced 1 AgentNetarsudil Ophth Sol 0.02% Monotherapy - Replaced 2 AgentsNetarsudil Ophth Sol 0.02% Concomitant Therapy
Intraocular Pressure (IOP)-16.9 ± 16.35-2.3 ± 16.230.2 ± 8.81-17.0 ± 16.81
Statistical analysis
  • Netarsudil Ophth Sol 0.02% Monotherapy - Tx Naïve At Baseline vs Netarsudil Ophth Sol 0.02% Monotherapy - Replaced 1 Agent vs Netarsudil Ophth Sol 0.02% Monotherapy - Replaced 2 Agents vs Netarsudil Ophth Sol 0.02% Concomitant Therapy ·

Adverse events

Collected over Adverse event data was collected during the course of the 12-week treatment period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Netarsudil Ophthalmic Solution 0.02% Monotherapy0/99 (0%)2/99 (2%)43/99 (43.4%)
Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy0/161 (0%)1/161 (0.6%)58/161 (36%)
Most frequent serious events
Most frequent serious events
EventNetarsudil Ophthalmic Solution 0.02% MonotherapyNetarsudil Ophthalmic Solution 0.02% Concomitant Therapy
Malignant Melanoma of EyelidNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/990/161
PneumoniaInfections and infestations1/990/161
Cellulitis Lower Left ExtremityInfections and infestations0/991/161
Most frequent other events
Most frequent other events
EventNetarsudil Ophthalmic Solution 0.02% MonotherapyNetarsudil Ophthalmic Solution 0.02% Concomitant Therapy
Conjunctival HyperemiaEye disorders22/9932/161
Vision BlurredEye disorders9/9910/161
Conjunctival HemorrageEye disorders6/998/161
Instillation Site PainEye disorders6/998/161

Baseline characteristics

Modified intent to treat (mITT) population included all subjects who received at least 1 dose of study medication and had at least 1 follow-up visit with a completed IOP measurement.

Age, Continuous
Age, Continuous(years)Netarsudil Ophthalmic Solution 0.02% MonotherapyNetarsudil Ophthalmic Solution 0.02% Concomitant TherapyTotal
Mean67.2 ± 11.8567.2 ± 10.5367.2 ± 11.02
Sex: Female, Male
Sex: Female, Male(Participants)Netarsudil Ophthalmic Solution 0.02% MonotherapyNetarsudil Ophthalmic Solution 0.02% Concomitant TherapyTotal
Female5791148
Male346094
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Netarsudil Ophthalmic Solution 0.02% MonotherapyNetarsudil Ophthalmic Solution 0.02% Concomitant TherapyTotal
Hispanic or Latino11819
Not Hispanic or Latino80143223
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Netarsudil Ophthalmic Solution 0.02% MonotherapyNetarsudil Ophthalmic Solution 0.02% Concomitant TherapyTotal
American Indian or Alaska Native101
Asian033
Native Hawaiian or Other Pacific Islander000
Black or African American134558
White77102179
More than one race011
Unknown or Not Reported000
08

Study locations

22 sites
  • Atlantis Eyecare
    Huntington Beach, California 92647, United States
  • Harvard Eye Associates
    Laguna Hills, California 92653, United States
  • North Bay Eye Associates, Inc
    Petaluma, California 94954, United States
  • Shettle Eye Research Inc
    Largo, Florida 33773, United States
  • Center For Sight
    Sarasota, Florida 34238, United States
  • Coastal Research Associates, LLC
    Roswell, Georgia 30076, United States
  • Wheaton Eye Clinic, Ltd
    Wheaton, Illinois 60187, United States
  • Stiles Eyecare Excellence and Glaucoma Institute, PA
    Overland Park, Kansas 66213, United States
  • Gaddie Eye Centers, LLC
    Louisville, Kentucky 40241, United States
  • Glaucoma Consultants
    Baltimore, Maryland 21204, United States
  • Tekwani Vision Center
    Saint Louis, Missouri 63128, United States
  • Mark J. Weiss, M.D., Inc.
    Tulsa, Oklahoma 74104, United States
  • Scott & Christie and Associates, PC
    Cranberry Township, Pennsylvania 16066, United States
  • Valley Eye Professionals, LLC
    Huntingdon Valley, Pennsylvania 19006, United States
  • Carolina Cataract & Laser Center
    Ladson, South Carolina 29456, United States
  • Total Eye Care, PA
    Memphis, Tennessee 38119, United States
  • VRF Eye Specialty Group
    Memphis, Tennessee 38120, United States
  • Advancing Vision Research
    Nashville, Tennessee 37204, United States
  • Keystone Research
    Austin, Texas 78731, United States
  • Cataract & Glaucoma Center
    El Paso, Texas 79902, United States
  • Houston Eye Associates
    Houston, Texas 77025, United States
  • The Eye Centers of Racine and Kenosha
    Racine, Wisconsin 53405, United States
09

References and documents

Publications

  • Zaman F, Gieser SC, Schwartz GF, Swan C, Williams JM. A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting. Curr Med Res Opin. 2021 Jun;37(6):1011-1020. doi: 10.1080/03007995.2021.1901222. Epub 2021 Mar 27. PubMed 33733980 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jul 2019, 6 months.

Results were first posted in Sep 2020, 1 year 2 months after primary completion.

Of 45 phase 4 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2019
First posted
Jan 17, 2019
StartActual
Dec 27, 2018
Primary completionActual
Jul 26, 2019
CompletionActual
Jul 26, 2019
Results first posted
Sep 29, 2020
Last update
Sep 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03808688
Responsible party
Sponsor
First posted
Jan 17, 2019
Start date
Dec 27, 2018
Primary completion
Jul 26, 2019
Completion
Jul 26, 2019
Results posted
Sep 29, 2020
Last update
Sep 29, 2020

Study contacts

David Hollander, MD, MBA
study director · Aerie Pharmaceuticals, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion